# Proteomic and histopathologic profiling reveal molecular features and clinical biomarkers of coronary atherosclerosis

## TL;DR

This study identifies molecular features and potential biomarkers for coronary atherosclerosis using proteomic and histopathologic profiling across different stages of the disease.

## Contribution

The study provides new insights into proteomic changes during atherosclerosis progression and introduces a three-protein biomarker panel for diagnosing coronary artery disease.

## Key findings

- Complement and coagulation cascades and extracellular matrix organization are progressively dysregulated during atherosclerosis progression.
- THBS1, ECM2, and C1R proteins form a robust biomarker panel for diagnosing coronary artery disease with high AUC values.
- The biomarker panel distinguishes stable CAD from controls and identifies acute coronary syndrome patients effectively.

## Abstract

The molecular features of coronary atherosclerosis progression remain incompletely understood. A comprehensive characterization of coronary proteome dynamics during atherosclerosis progression could facilitate the identification of novel biomarkers for early detection of plaque initiation and risk assessment of plaque destabilization. We performed proteomics on human coronary artery specimens representing five progressive histopathologic stages of atherosclerosis according to the modified AHA classification, including adaptive intimal thickening (AIT), pathological intimal thickening (PIT), fibroatheroma (FA), thin cap fibroatheroma (TCFA), and ruptured plaque (RP). The results revealed progressive dysregulation of complement and coagulation cascades and extracellular matrix (ECM) organization during histopathologic progression, particularly in plaque initiation and destabilization. Integrated single-cell RNA sequencing data showed that complement and coagulation pathways were predominantly upregulated in fibroblasts and macrophages, while ECM organization was elevated in fibroblasts and smooth muscle cells. Plasma proteomics in a discovery cohort identified THBS1, ECM2, and C1R proteins as robust diagnostic biomarkers from among the overlapping complement and ECM proteins found in the tissue proteomics. The combination of these biomarkers achieved area under the curve (AUC) values of 0.831 in the training set and 0.764 in the test set for identifying coronary artery disease (CAD). In both the discovery cohort and the external validation cohort, this biomarker panel distinguished stable CAD from non-stenosis controls (AUC: 0.765 and 0.841, respectively) and identified ACS patients (AUC: 0.786 and 0.822, respectively). These findings elucidate the proteomic landscape of atherosclerosis progression and establish a three-protein biomarker panel with potential for CAD diagnosis.

The online version contains supplementary material available at 10.1186/s40364-025-00846-3.